Retina Implant AG's lead researcher to present at annual EURETINA Congress

Retina Implant AG's lead researcher to present at annual EURETINA Congress PR Newswire MILAN, Italy, Sept. 5, 2012 - Professor Eberhart Zrenner to present results from Retina Implant AG's second human clinical trial MILAN, Italy, Sept. 5, 2012 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that results from the Company's second human clinical trial will be presented at the 12th EURETINA Congress, in Milan, 6-9 September. On Friday, 7 September at 16:45 CEST Professor Eberhart Zrenner, director and chairman of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the University of Tuebingen, Germany and lead clinical trial investigator for Retina Implant AG, will present preliminary data obtained to- date from the Company's second human multi-centre clinical trial taking place in Germany, the UK and Hong Kong. "We are encouraged by the results achieved in our second human clinical trial thus far as they represent an impactful advance in Retina Implant's technology that could greatly enhance the quality of life for people with retinitis pigmentosa, an incurable, blinding disease," said Professor Eberhart Zrenner, founding director of the Institute for Ophthalmic Research in Tuebingen, Germany.